winningtrades.com Open in urlscan Pro
104.19.240.93  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Free SMS Alerts
October 22, 2024 - Sponsored by Therma Bright Inc.
This Is Why THRM.V Is Our #1 Winning Momentum Trade This Week
🇺🇸 TBRIF    🇨🇦 THRM.V    🇩🇪 JNX


TRADING SESSION - TUE, OCT 22, 2024


Click to expand
Therma Bright Inc. (TSXV: THRM), (OTCQB: TBRIF), (FRA: JNX) is a triple-listed
public entity, on the cusp of transforming the landscape of diagnostic and
medical device technologies. With a diversified portfolio of FDA-approved and
pipeline products that target some of the largest medical markets globally,
Therma Bright might represent a rare opportunity to get in early before the
market catches up with its true value.
When it comes to finding the next big winner in the stock market, many investors
make the mistake of chasing high-priced stocks, hoping for small, incremental
gains. But as any seasoned trader will tell you, the real strategy for securing
substantial returns is identifying a company that’s severely undervalued—a
company with enormous growth potential that has yet to be fully recognized by
the market.

But before we delve into Therma Bright’s impressive array of cutting-edge
innovations, let’s first address a fundamental principle of successful
investing: diversification.


3 REASONS YOU'LL BE GLAD YOU ADDED TSXV: THRM TO YOUR WATCHLIST

📈 With a market cap of just $21M and an ultra low share price, we believe
Therma Bright displays all the characteristics of a Winning Trade.
🔥 Therma Bright is a multi product company with patents and FDA approvals. Its
Venowave product was just approved for a permanent US insurance code.

💡 Beyond Therma Bright's approved and market ready products, it's cutting edge
Preva stroke treatment product has achieved its 3rd human trial success.
THRM.V Has Multiple Winning Products Inside Its Tiny $21m Market Cap
For many blue-chip companies, success isn’t built on the back of a single
product. Companies like Tesla and Apple have thrived by diversifying their
product lines, offering consumers a suite of complementary products that protect
the company from the risks of hinging everything on a single offering. Tesla is
not just about electric cars; it’s a leader in solar energy, AI technology, and
battery storage. The same logic applies to Therma Bright.

Unlike companies that bet the farm on one breakthrough technology, Therma Bright
offers investors exposure to a diversified pipeline of products, each targeting
massive global markets. This diversification minimizes risk while amplifying the
potential for significant returns. All of this is wrapped up in a low float and
unbelievable $21m market cap. Let’s take a look at these pillars of Therma
Bright’s growth strategy.


Venowave VW5: A Game-Changer in Blood Clot Prevention

At the heart of Therma Bright’s product portfolio is the Venowave VW5, a
patented, FDA-approved device designed to treat and alleviate the symptoms of
poor circulation. Whether it’s preventing deep vein thrombosis (DVT) or managing
chronic venous insufficiencies, the Venowave VW5 stands out in a market that’s
worth more than $4 billion globally.

Poor circulation is not just a minor inconvenience—it’s a life-threatening
condition that affects over 900,000 patients in the U.S. alone. Blood clots can
lead to heart attacks, strokes, and other serious medical conditions. The
Venowave VW5 addresses this issue by using a wave motion to force blood from the
feet and legs back to the heart, thereby preventing clotting and pooling.

With FDA approval in hand, Therma Bright has a clear path to market for the
Venowave VW5. The device has secured a new HCPCS Level II designation from the
U.S. Department of Health & Human Services, which means it is eligible for
patient reimbursement through Medicare and Medicaid Services (CMS). This is a
crucial competitive advantage that paves the way for widespread adoption in
hospitals, clinics, and even home care settings.

What does this mean for investors? It means the Venowave VW5 is not just a
concept or a speculative technology—it’s a fully approved, market-ready device
that’s poised to capture significant market share in a billion-dollar industry.




PREVA™: The Future of Ischemic Stroke Treatment

While the Venowave VW5 addresses blood clots in the legs, Therma Bright’s
investment in Inretio brings the company into the rapidly growing ischemic
stroke treatment market—a $4.3 billion global opportunity. Ischemic strokes
occur when a blood clot blocks the flow of oxygen to the brain, and current
treatments often fall short in terms of effectiveness and safety.

That’s where PREVA™ comes in. This revolutionary clot-retriever, currently in
clinical trials, offers a new approach to stroke treatment. Unlike traditional
devices that can be cumbersome and ineffective, PREVA™ features a patented
protective basket that minimizes the risk of complications during the clot
retrieval process.

Early trials have shown an 80% success rate—far superior to the 50% success rate
of existing clot retrieval technologies. As PREVA™ moves through the regulatory
process, it holds the potential to become a game-changer in stroke treatment,
offering safer and more effective outcomes for patients around the world.

For investors, PREVA™ is yet another example of Therma Bright’s commitment to
tackling some of the most pressing medical challenges with innovative,
next-generation solutions.





InStatin and Invixa: Revolutionizing Respiratory Health

Therma Bright’s diversified product portfolio also extends into the respiratory
health sector, where the company has a 17% equity stake in InStatin and a 60%
stake in Invixa. Both companies are focused on developing inhaled statin
therapies for the treatment of asthma, Chronic Obstructive Pulmonary Disease
(COPD), and even COVID-19.

For decades, statins have been widely used to manage cardiovascular conditions,
but InStatin and Invixa are repurposing these drugs to address respiratory
diseases. By delivering statins directly to the lungs via inhalation, these
therapies offer a greater therapeutic effect with fewer side effects than
traditional treatments.

Why is this significant? Because respiratory diseases like COPD and asthma are
massive global markets. COPD alone affects over 300 million people and is the
third leading cause of death worldwide. Asthma affects an additional 300 million
people, contributing to hundreds of thousands of deaths each year. With a total
addressable market of more than $16 billion, InStatin’s and Invixa’s therapies
could represent a major breakthrough in the treatment of these chronic diseases.

What’s more, the use of a repurposed drug with a well-documented safety profile
means that regulatory approval could be faster and less costly than for entirely
new drug candidates. This positions Therma Bright to capitalize on a massive
market opportunity with reduced risk.


The Digital Cough Test: AI-Powered Predictive Healthcare

In an era where artificial intelligence is transforming industries, Therma
Bright’s exclusive licensing of the Digital Cough Test (DCT) marks its entry
into the realm of AI-powered healthcare. The DCT app uses AI to analyze cough
sounds and provide rapid, accurate results to monitor what is causing a
patient's cough. Users simply record a three-second cough sample on their
smartphone, and the app does the rest. The information is then sent to a doctor
to analyze the AI produced data. The doctor can then provide the treatment
protocol.

The potential applications of this technology are vast. With growing interest in
digital cough screening, the DCT could revolutionize the way we detect and
monitor respiratory conditions, from the common cold to chronic coughs. In fact,
the app is already being considered for a U.S. clinical trial with a leading
pharmaceutical company.

For Therma Bright, the DCT represents an opportunity to disrupt a $10 billion
market dominated by outdated lateral flow tests. As AI continues to reshape the
healthcare landscape, the DCT could emerge as a key player in the shift from
reactive sick care to predictive health monitoring.




FDA Approvals Are a Market Catalyst

One of the biggest hurdles for companies in the biomedical space is securing FDA
approval for their products. Many promising technologies never make it to market
because they run out of funding or patience during the lengthy approval process.
But this is where Therma Bright stands apart from the pack.

Several of Therma Bright’s products, including the Venowave VW5, have already
cleared FDA approval, while others are making significant progress in clinical
trials. This de-risks the investment thesis considerably, as the company is not
solely reliant on future regulatory success to drive growth.


The $19m Market Cap Mystery: Why We Believe THRM.V is Severely Undervalued

Perhaps the most intriguing aspect of Therma Bright’s story is its market
capitalization. Despite its broad portfolio of FDA-approved products and
pipeline technologies, the company’s market cap sits at just $21 million. For a
company with multiple revenue-ready products, this is a glaring indication that
Therma Bright is flying under the radar.

To put this in perspective, companies with similar product pipelines and FDA
approvals often command valuations in the hundreds of millions, if not billions,
of dollars. This suggests that Therma Bright is significantly undervalued and
could present an incredible opportunity for early investors.


The Management Team: Visionaries with Proven Track Records

Behind every successful company is a team of leaders who not only understand the
market but also have the experience to bring innovative products to life. Therma
Bright’s management team is comprised of seasoned veterans with decades of
experience in the medical technology and healthcare sectors.

At the helm is CEO Rob Fia, a business leader with extensive expertise in
corporate finance, product development, and strategic partnerships. Under his
guidance, Therma Bright has successfully navigated regulatory challenges,
acquired valuable medical technologies, and built relationships with key
industry players.

Fia’s strategic vision has been complemented by a team of experts, including key
advisors and industry specialists who bring deep knowledge in areas like
clinical research, regulatory affairs, and medical device commercialization.
This combination of financial acumen and technical expertise ensures that Therma
Bright is well-positioned to capitalize on its diverse product portfolio and
execute on its growth strategy.

What sets Therma Bright’s leadership apart is their commitment to delivering
shareholder value while advancing innovations that address some of the most
pressing healthcare challenges of our time. The team’s track record speaks for
itself, and investors can take confidence in the fact that Therma Bright’s
management is dedicated to driving both product success and long-term company
growth.




All This For A $21m Market Cap? Why We Think THRM.V Is Undervalued And A Major
Winning Trade

Therma Bright is not your typical small-cap biotech. With a diversified
portfolio of medical device technologies, multiple billion-dollar market
opportunities, and a clear path to regulatory approval, the company could be
uniquely positioned for long-term growth. Add in the fact that its market cap is
a fraction of what it could—and we believe should—be, could result in all the
ingredients for a true Winning Trade opportunity.

The question is: Will you recognize it before the rest of the market catches on?


WINNING TRADES BEFORE THEY HAPPEN

Get Free SMS Alerts


THRM.V FEATURED NEWS

Thu, Oct 10, 2024 - Therma Bright Announces Quantify Medical as Nationwide U.S.
Distribution Partner from August 22, 2024 Press Release
Editor Highlight: Following the conclusion of the test, Quantify Medical looks
to acquire the remaining Venowave VW5 inventory. If all inventory were to be
purchased by the distributor it would represent up to USD $2.38M in HCPCS Level
II code E068 reimbursement.
Mon, Sep 23, 2024 - InStatin Secures Mountain West Research Discovery Study
Agreement
Editor Highlight: The research will help clarify how to properly target delivery
of the solution's active pharmaceutical ingredients (API) in the lungs to
enhance the efficacy, bioavailability, and overall treatment outcomes.
Wed, Sep 12, 2024 - Therma Bright Welcomes Medical Device & Pharmaceutical
Veteran Douglas S. Sommerville to Its Advisory Board
Editor Highlight: Mr. Sommerville previously served as the Head of Country for
Teva Canada Limited, where he oversaw the Canadian operations of Teva's generic
drug business, the pharmaceutical firm's third-largest global subsidiary with
sales exceeding $1.3 billion.
Tue, Aug 27, 2024 - Therma Bright Major Milestone: Portfolio Company Inretio's
Preva(R) Device Achieves 3rd Human Trial Success
Editor Highlight: This cutting-edge technology is uniquely designed to safely
and effectively restore blood flow in patients suffering from Ischemic strokes,
even when traditional treatments, like tPA, fall short.
Thu, Aug 22, 2024 - Therma Bright Secures Nationwide U.S. Distribution Partner
For Venowave
Editor Highlight: With strong distribution network interest, Therma Bright
expects its current inventory of 2,000 units-representing up to USD $2.38
million in reimbursement value-to be quickly sold with strong demand for
additional orders.
Mon, Aug 19, 2024 - Therma Bright's Venowave VW5 Secures Permanent HCPCS Code
E0683 from U.S. DHHS's Centers for Medicare & Medicaid Services
Editor Highlight: "We're pleased that the Centers for Medicare and Medicaid has
approved our permanent code request, as well as the reimbursement pricing and
the new HCPCS Level II designation for our Venowave VW5 device," shared Rob Fia,
CEO of Therma Bright.

IMPORTANT NOTICE AND DISCLAIMER
Copyright 2024 © WinningTrades.com is owned and operated by Wired IR LLC, a
Wyoming Corporation. For more information, please contact editor@wiredir.com.

To more fully understand any subscription, website, application, product, or
other service (“Services”) including WinningTrades.com, owned or operated by
Wired IR LLC (together with its affiliates, owners, and control persons, the
“Publisher”), please carefully read the disclosure below.

This is an issuer-paid advertisement. Therma Bright Inc. has paid Publisher
$162,000 in cash for marketing services, including communicating information
about the Company to the Public. This advertorial (“advertisement” or
“Advertorial”) is part of those issuer-paid marketing services. The contract
with Therma Bright Inc. was effective on Sep 16 2024 and continues until Dec 1
2024 (the “Term”), unless terminated by written notice of either party prior to
the end of the Term or extended. As a result of this advertisement and other
marketing efforts, Publisher may also receive advertising revenue from new
advertisers and collect email addresses from readers that it may be able to
monetize. As of the date of this advertisement, Publisher holds no securities of
the Company and does not intend to purchase any securities during the Term. This
advertisement and other marketing efforts may increase investor and market
awareness, which may result in an increased number of shareholders owning and
trading the securities of the Company, increased trading volume, and possibly an
increased share price, which may or may not be temporary and could decrease once
the marketing services have ended.

For Educational and Information Purposes Only; Not Investment Advice
This advertisement is for educational and informational purposes only. All
material information contained in this advertisement is based on information
generally available to the public, which public information is believed to be
reliable and accurate. Nevertheless, Publisher cannot guarantee the accuracy or
completeness of the information. This advertisement does not purport to be a
complete analysis of this Company or any company’s financial position. This
advertisement or any statements made in it are not, and should not be construed
to be, personalized investment advice directed to or appropriate for any
particular individual. The statements made in this advertisement should NOT be
relied upon for purposes of investing in the Company that is the subject of the
Advertorial or any other companies mentioned in this Advertorial, nor should
they be construed as a personalized recommendation to buy, sell, or hold any
position in any security mentioned in this Advertorial or any other security or
strategy. It is strongly recommended that you consult a licensed or registered
professional before making any investment decision.

SUBSTANTIAL RISK INVOLVED
Any individual who chooses to invest in the securities of the Company profiled
in the Advertorial or any securities of the companies mentioned in this
advertisement should do so with caution. Although this advertisement focuses on
the positive features of the Company profiled and its securities, you must keep
in mind that investing or transacting in these or any securities involves
substantial risk; you may lose some, all, or possibly more than your original
investment. Readers of this advertisement bear responsibility for their own
investment research and decisions and should use information from this
advertisement only as a starting point for doing additional independent research
to allow individuals to form their own opinion regarding investments. It is easy
to lose money investing or trading, and we recommend always seeking individual
advice from a licensed or registered professional and educating yourself as much
as possible before considering any investments.

Not an Investment Advisor or Registered Broker
Neither Publisher nor any of their owners, employees, or independent contractors
is currently registered as a securities broker-dealer, broker, investment
advisor (IA), or IA representative with the U.S. Securities and Exchange
Commission, any state securities regulatory authority, or any self-regulatory
organization.

USE OF FORWARD-LOOKING STATEMENTS
Certain statements made in this advertisement may constitute forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Exchange Act of 1934. Forward-looking statements often
include words such as “believes,” “anticipates,” “estimates,” “expects,”
“projects,” “intends,” or other similar expressions of future performance or
conduct. Forward-looking statements are based on expectations, estimates, and
projections at the time the statements are made and are not statements of
historical fact. They involve many risks and uncertainties that could cause
actual results or events to differ materially from those presently anticipated.
There is no guarantee that past performance will be indicative of future
results. Publisher does not undertake an obligation to update forward-looking
statements in light of new information or future events.

TRADEMARKS
All trademarks used in this advertisement are the property of their respective
trademark holders, and no endorsement by such owners of the contents of the
advertisement is made or implied.

Wired IR LLC and their affiliates and control persons (the “Publisher”) are in
the business of publishing favorable information and/or advertisements (the
“Information”) about the securities of publicly traded companies (each an
“Issuer” or collectively the “Issuers”) in exchange for compensation (the
“Campaigns”). Persons receiving the Information are referred to as the
“Recipients.” The person or entity paying the Publisher for the Campaign is
referred to herein as the “Paying Party.” The Paying Party may be an Issuer, an
affiliated or non-affiliate shareholder of an Issuer, or another person hired by
the Issuer or an affiliate or non-affiliate shareholder of the Issuer. The
nature and amount of compensation paid to the Publisher for the Campaign and
creating and/or publishing the Information about each Issuer is set forth below
under the heading captioned, “Compensation.”

This website provides information about the stock market and other investments.
This website does not provide investment advice and should not be used as a
replacement for investment advice from a qualified professional. This website is
for informational purposes only. The Author of this website is not a registered
investment advisor and does not offer investment advice. You, the reader, bear
responsibility for your own investment decisions and should seek the advice of a
qualified securities professional before making any investment.

Nothing on this website should be considered personalized financial advice. Any
investments recommended herein should be made only after consulting with your
personal investment advisor and only after performing your own research and due
diligence, including reviewing the prospectus or financial statements of the
issuer of any security.

Wired IR LLC, its managers, employees, affiliates, and assigns (collectively the
"Publisher") do not make any guarantee or warranty about the advice provided on
this website or what is otherwise advertised above.

To the maximum extent permitted by law, the Company disclaims all liability in
the event any information, commentary, analysis, opinions, advice, and/or
recommendations provided herein prove to be inaccurate, incomplete, or
unreliable, or result in any investment or other losses.

Always do your own research and consult with a licensed investment professional
before investing. This communication is never to be used as the basis for making
investment decisions and is for entertainment purposes only. At most, this
communication should serve only as a starting point to do your own research and
consult with a licensed professional regarding the companies profiled and
discussed. Conduct your own research.